STOK

Stoke Therapeutics, Inc. Common Stock · XNAS · 131 sessions on record

$26.00▲ +0.12 · +0.5%from $25.88 the session before · Sep 30, 2026 close · end of day

Open: $26.12
High: $26.69
Low: $25.88
Day's range: $0.813.1% of the previous close
VWAP: $26.07close −0.27% from it
Volume, shares: 1.87M2.17× the 20-session average
Traded, $: $48.9M
Trades: 13K140 shares per trade
Previous close: $25.88+0.12 to the close
Market cap: $1.68Bat the close of Sep 30

Day range15% of the way up

$25.88$26.69

52-week range14% of the way up

$24.21 Sep 28$37.35 Apr 17

−30% from the high · +7.4% from the low

Options

No listed options on STOK

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

131 sessions on file · from Mar 25

STOK close
S&P 500, rebased

Session read · latest close: Sep 30, 2026
Close $ · day %: $26.00▲ +0.5% on the previous close
Against S&P 500: S&P 500 −0.2%+0.7 pp difference on the day
Against the averages: below 20 · below 5020-session $28.12 (−7.6%) · 50-session $30.04 (−13%)
Volume: 2.17×the previous 20 sessions · 1.87M shares
Extremes on the day: none

Quarterly results

consolidated · latest filed Aug 3, 2026 · SEC filings

Revenue $9.3M, −33% on a year earlier; profit −$61.6M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session

Quarterly results of STOK on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $	Market on the day
Jun 2026filed Aug 3	$9.3M	▼ −33%	−$61.6M	—	-0.93	▲ +7.1%S&P 500 +1.8% · +5.3 pp
Mar 2026filed Aug 3	$6.2M	▼ −96%	−$50.0M	▼ −140%	-0.79	▲ +7.1%S&P 500 +1.8% · +5.3 pp
Dec 2025filed Mar 16	$1.4M	▼ −94%	−$57.9M	—	-0.97	—not reached
Sep 2025filed Nov 4	$10.6M	▲ +120%	−$38.3M	—	-0.65	—not reached
Jun 2025filed Aug 3	$13.8M	▲ +190%	−$23.5M	—	-0.40	▲ +7.1%S&P 500 +1.8% · +5.3 pp
Mar 2025filed Aug 3	$158.6M	▲ +3,700%	$112.9M	—	1.90	▲ +7.1%S&P 500 +1.8% · +5.3 pp
Dec 2024filed Mar 18	$22.6M	▲ +710%	−$10.5M	—	-0.15	—not reached
Sep 2024filed Nov 4	$4.9M	▲ +48%	−$26.4M	—	-0.47	—not reached

By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends

Financial-year results of STOK on the consolidated basis, summed from the quarters filed
Year	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $
FY25to Dec 2025	$184.4M	▲ +400%	−$6.9M	—	-0.12
FY24to Dec 2024	$36.6M	▲ +320%	−$89.0M	—	-1.65
FY23to Dec 2023	$8.8M	▼ −29%	−$104.7M	—	-2.38
FY22to Dec 2022	$12.4M	—	−$101.1M	—	-2.60
FY21to Dec 2021	—	—	−$85.8M	—	-2.34

Fundamentals

consolidated · filings to Jun 2026 · close $26.00 on Sep 30

4.9 times book value, revenue −86% over twelve months, market cap $1.68B.

Valuation

Market cap: $1.68Bon Sep 30
Price to earnings: —
Trailing EPS: $-3.34diluted · consolidated · four quarters to Jun 2026
Price to book: 4.9consolidated · balance sheet to Jun 2026
Book value a share: $5.36consolidated · balance sheet to Jun 2026
Debt to equity: —
Return on equity: -61%trailing profit over average equity · consolidated
Dividend yield: —
Price to sales: 61market cap over revenue, four quarters to Jun 2026
Shares outstanding: 64.5Mon Sep 30

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: $27.6Mfour quarters to Jun 2026
Revenue growth, 12 months: ▼ −86%against the twelve months before
Revenue 3-year CAGR: ▲ +46%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months: −$207.9Mfour quarters to Jun 2026
Profit growth, 12 months: ▼ −500%against the twelve months before
Profit 3-year CAGR: —

PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks

Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
Stock	Market cap	P/E	P/B	Close $
REGNRegeneron Pharmaceuticals Inc	$71.24Bon Sep 30	19consolidated	2.3	$758.27
UTHRUnited Therapeutics Corp	$23.24Bon Sep 30	19consolidated	3.6	$541.89
RPRXRoyalty Pharma plc Class A Ordinary Shares	$22.65Bon Sep 30	31consolidated	—	$58.36
BMRNBioMarin Pharmaceuticals Inc	$11.61Bon Sep 30	150consolidated	1.8	$60.00
LQDALiquidia Corporation Common Stock	$2.71Bon Sep 30	22consolidated	14	$30.26
ANIPANI Pharmaceuticals, Inc.	$1.77Bon Sep 30	16consolidated	3.0	$72.65
STOKStoke Therapeutics, Inc. Common Stock	$1.68Bon Sep 30	—	4.9	$26.00
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares	$995.7Mon Sep 30	—	2.3	$11.70
JBIOJade Biosciences, Inc. Common Stock	$893.5Mon Sep 30	1.7consolidated	2.0	$14.05
CLYMClimb Bio, Inc. Common Stock	$658.8Mon Sep 30	—	2.8	$11.47

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 220% of shares, BlackRock, Inc. the largest at 18%, RTW INVESTMENTS, LP 17% and FMR LLC 16%, as filed for the quarter to Jun 2026.

18.2%17.4%16.5%169.6%

Held by 13F managers: 220%of shares outstanding
Shares held: 143M+2.8% on Mar 2026 among managers filing both
Managers holding: 190186 a quarter earlier
Largest holder: 18%BlackRock, Inc.

Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter

Largest 13F holders of STOK
Manager	Shares	Of outstanding	Value	Change on quarter
BlackRock, Inc.	11.8M	18%	$384.6M	+983K
RTW INVESTMENTS, LP	11.2M	17%	$368.0M	unchanged
FMR LLC	10.6M	16%	$347.7M	−141K
Lynx1 Capital Management LP	8.08M	13%	$264.3M	−1.45M
Redmile Group, LLC	7.89M	12%	$258.2M	−436K
WELLINGTON MANAGEMENT GROUP LLP	7.04M	11%	$230.3M	+847K
MORGAN STANLEY	6.91M	11%	$226.0M	+59K
BAKER BROS. ADVISORS LP	6.67M	10%	$218.4M	unchanged
TORONTO DOMINION BANK	6.35M	9.8%	$207.7M	unchanged
STATE STREET CORP	5.7M	8.8%	$186.7M	+1.15M

Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

STOK insider trades
Insider	Trade	Shares	Price	Held after
Allan JonathanOfficer	sold · Jun 16, 2026	1,457	$29.95	18,086
Ticho BarryOfficer	sold · Jun 1, 2026	1,795	$30.58	34,826
Ticho BarryOfficer	sold · May 1, 2026	2,243	$32.79	36,621
Ticho BarryOfficer	sold · Apr 1, 2026	1,838	$32.66	38,864
Allan JonathanOfficer	sold · Mar 20, 2026	8,692	$33.64	20,144
Allan JonathanOfficer	sold · Mar 20, 2026	601	$34.41	19,543
Hoitt JasonOfficer	sold · Mar 18, 2026	139	$31.79	10,306
Hoitt JasonOfficer	sold · Mar 18, 2026	1,762	$31.28	10,445
Hoitt JasonOfficer	sold · Mar 17, 2026	748	$33.38	12,207
Hoitt JasonOfficer	sold · Mar 17, 2026	1,033	$32.74	12,955

Corporate actions

exchange records

No corporate action on record for STOK yet.

Price history

131 sessions on record · to Sep 30 · end of day

STOK is −15.8% over 20 sessions against the S&P 500's +0.1%, 30% below its 52-week high, realised volatility 53% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions

Returns of the stock and S&P 500 over six windows, longest first
Window	From $	STOK %	S&P 500 %	Difference pp
120 sessionssince Apr 9	$35.15	▼ −26%	▲ +12%	−38
60 sessionssince Jul 7	$33.02	▼ −21%	▲ +2.0%	−23
20 sessionssince Sep 1	$30.89	▼ −16%	▲ +0.11%	−16
5 sessionssince Sep 23	$26.11	▼ −0.42%	▼ −0.67%	+0.25
1 sessionsince Sep 29	$25.88	▲ +0.46%	▼ −0.21%	+0.67

Averages of the closeclose against each average

5-session average: $25.49close +2.0% from it
20-session average: $28.12close −7.5% from it
50-session average: $30.04close −13% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: $1.34.8% of the close
Average day's range, 20: $1.14.3% of the close
Volume against 20 sessions: 2.17×1.87M vs 921K average

Volatility and co-movement with S&P 500annualised from daily returns

Realised volatility, 20: 53%≈ ±3.3% a session · moved more than that on 4 of 20
Realised volatility, 60: 47%≈ ±3.0% a session · moved more than that on 14 of 60
Beta to S&P 500, 60: 1.16moved with S&P 500 on 33 of 60 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 7 up · 13 downof 20
Last 60 sessions: 28 up · 31 downof 59
Best session, 250: ▲ +7.1%Aug 4
Worst session, 250: ▼ −11%Sep 23

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 52% of reported volume on Sep 30, 2026, against 58% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume

STOK daily short-sale volume
Session	Short volume	Reported volume	Short share
Sep 30, 2026	178K	339K	52.5%
Sep 29, 2026	135K	191K	70.6%
Sep 28, 2026	288K	389K	74.1%
Sep 25, 2026	216K	327K	66.0%
Sep 24, 2026	348K	599K	58.1%
Sep 23, 2026	415K	502K	82.6%
Sep 22, 2026	116K	193K	60.1%
Sep 21, 2026	130K	270K	48.2%
Sep 18, 2026	127K	189K	67.3%
Sep 17, 2026	457K	554K	82.6%

Filings

SEC EDGAR · newest first

STOK SEC filings
Filed	Form	Report date
Sep 30, 2026	SCHEDULE 13G	—
Sep 25, 2026	4	Sep 23, 2026
Sep 25, 2026	3	Sep 23, 2026
Sep 25, 2026	8-K	Sep 22, 2026
Sep 3, 2026	4	Sep 1, 2026
Aug 18, 2026	4	Aug 14, 2026
Aug 18, 2026	4	Aug 14, 2026
Aug 18, 2026	4	Aug 14, 2026
Aug 14, 2026	SCHEDULE 13G/A	—
Aug 12, 2026	SCHEDULE 13G/A	—
Aug 6, 2026	SCHEDULE 13G/A	—
Aug 5, 2026	4	Aug 3, 2026
Aug 3, 2026	144	—
Aug 3, 2026	8-K	Aug 3, 2026
Aug 3, 2026	424B5	—
Aug 3, 2026	S-8	—
Aug 3, 2026	10-Q	Jun 30, 2026
Aug 3, 2026	8-K	Aug 3, 2026
Jul 17, 2026	4	Jul 15, 2026
Jul 17, 2026	3	Jul 13, 2026
Jul 17, 2026	4	Jul 16, 2026
Jul 6, 2026	4	Jul 1, 2026
Jul 1, 2026	144	—
Jun 30, 2026	8-K	Jun 30, 2026
Jun 18, 2026	4	Jun 16, 2026

About Stoke Therapeutics, Inc. Common Stock

SEC and exchange records

Company: Stoke Therapeutics, Inc. Common Stock
Exchange: XNAS
Industry: Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK: 1623526
Sessions on record: 131
Price source: End of day · delayed
Computed: 1 Oct, 10:41 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.